Skip to main content

Table 1 Clinicopathological characteristics of metastatic lung cancer patients, treatment received and CTC’s features

From: Circulating tumor cells as marker of poor prognosis in metastatic lung cancer: a pilot study

Patient

G

TNM

Histological type

Last treatment pre-CTC collection

CTC/ml

CTM

Progression post-CTC collection (in months)

Death

Treatment post-CTC collection

Sites pre-CTC collection

Site post-CTC collection

1

Male

T4N3M1

C

untreated

1.0

no

4 months (D)

yes

cisplatin+gemcitabine

pleura, lymph nodes, pericardium, bone

pleura, lymph nodes, pericardium, bone

2

Male

T2N3M1

A

pemetrexed+carboplatin

3.0

yes

5 months

yes

docetaxel

lung, liver, lymph nodes

+lung, +liver, lymph nodes, bone

3

Female

T4N0M1

A

pemetrexed

12.0

yes

3 months

no

erlotinib/docetaxel/vinorelbine/nivolumab

lung, pleura

+lung, bone

4

Male

T4N0M1

A

pemetrexed

3.0

no

8 months

no

docetaxel/gemcitabine/navelbine

bone, lymph nodes, CNS

+bone, lymph nodes, CNS

5

Male

T2N0M1

A

gefitinib

8.0

no

5 months

yes

docetaxel/erlotinib

pleura, CNS

+pleura, +CNS

6

Female

T1N2M1

A

bevacizumab

2.0

yes

4 months

yes

erlotinib/pemetrexed/gemcitabine

lung, lymph nodes, adrenal

+lung, +lymph nodes, adrenal

7

Male

T4N3M1

A

untreated

1.0

no

24 months

no

erlotinib/carboplatin+paclitaxel+bevacizumab/pemetrexed

bone, CNS, lung

+bone, +CNS, lung

8

Female

T4N3M1

A

untreated

18.75

no

9 months

no

carboplatin+paclitaxel+bevacizumab/pemetrexed/crizotinib/ceritinib

lung

+lung, bone, CNS, lymph nodes

9

Female

T3N2M1

A

untreated

3.5

no

3 months

yes

carboplatin+pemetrexed/docetaxel

bone, pleura, lymph nodes

bone, pleura, lymph nodes, lung

10

Female

T1N1M1

A

cisplatin+vinorelbine

4.06

no

10 months

no

erlotinib

lung, CNS

+lung, +CNS

11

Male

M1

A

untreated

0.37

no

3 months (D)

yes

untreated

lung, bone, CNS

NT

12

Male

T3N0M1

C

cisplatin+pemetrexed

1.87

no

2 months

yes

gefitinib

liver, lymph nodes, pancreas

liver, lymph nodes, pancreas

13

Female

T4N0M1

A

untreated

0

no

12 months

yes

carboplatin+pemetrexed/docetaxel/gemcitabine

pleura, lymph nodes

pleura, lymph nodes, bone, CNS

14

Male

M1

A

untreated

3

no

3 months (D)

yes

untreated

lung, bone, lymph nodes, CNS, adrenal

NT

15

Male

M1

A

untreated

0

no

8 months

no

carboplatin+paclitaxel+bevacizumab/pemetrexed/docetaxel/nivolumab/erlotinib/gefitinib/gemcitabine

bone, lymph nodes, CNS, mesentery

+bone, +lymph nodes, CNS, mesentery, liver, lung

  1. Legend: Each line of chemotherapy was separated for slash symbol (/)
  2. G gender, CTC circulating tumor cell, CTM circulating tumor microemboli, CNS central nervous system, + progression at preexisting tumor site, NT not treated, D First progression was death, T tumor size, N lymph node commitment, M distant metastasis (AJCC) [18], C Carcinoma, A adenocarcinoma